Cleo Diagnostics (ASX:COV) is attempting to bring to market a simple blood test for the accurate and early diagnosis of ovarian cancer based on the novel patented CXCL10 biomarker, which is produced early and at high levels by ovarian cancers but is largely absent in nonmalignant disease. The test aims to distinguish benign from malignant growths in a standard format that will be readily compatible with existing equipment used by diagnostic laboratories worldwide | Investor presentation: https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02774453-3A636747
DY6
0.135
92.9%
EEL
0.001
-50%
LKY
0.042
82.6%
HCF
0.02
-44.4%
DTR
0.036
63.6%
DTM
0.003
-40%
DES
0.165
57.1%
MTB
0.003
-40%
HRE
0.029
52.6%
DYM
0.215
-34.8%
TMK
0.003
50%
JAV
0.002
-33.3%
WCN
0.034
47.8%
MIO
0.018
-33.3%
AZL
0.01
42.9%
VFX
0.002
-33.3%
YAR
0.007
40%
ANX
0.007
-30%
VRX
0.057
39%
IFG
0.005
-28.6%
WJL
0.895
37.7%
HLS
1.155
-26.2%
CMD
0.022
37.5%
XPN
0.015
-25%
VRL
0.022
37.5%
C29
0.035
-23.9%
BCB
0.475
33.8%
BB1
0.32
-21%
CRB
0.004
33.3%
1AD
0.004
-20%
GGE
0.004
33.3%
AVE
0.004
-20%
OSL
0.004
33.3%
PUR
0.037
-19.6%
PPY
0.012
33.3%
OPL
0.021
-19.2%
THB
0.012
33.3%
NWM
0.013
-18.8%
VEN
0.004
33.3%
EV1
0.009
-18.2%
